Demographics
| Patient | Age | Gender | LVEF | Aetiology | NYHA | Device | Antiarrhythmic drugs | Prior catheter ablation |
| 1 (STH) | 70s | M | 20 | Myocarditis | III | CRTD | A 300 mg once a day R 500 mg two times per day (intolerant Me) | 2 |
| 2 (NUTH) | 70s | F | 30 | Idiopathic | IV | CRTD | A 200 mg once a day | 3 |
| 3 (JCUH) | 70s | M | 45 | Ischaemic | II | ICD | A 200 mg once a day | 1 |
| 4 (NUTH) | 60s | M | 35 | Ischaemic | II | ICD | A 200 mg once a day | 3 |
| 5 (STH) | 60s | M | 15 | Ischaemic | II | CRTD | Me 300 mg three times a day (prior use of A, R) | 2 |
| 6 (NUTH) | 70s | F | 25 | Ischaemic | III | ICD | A 200 mg once a day (prior use of Me, P) | 2 |
| 7 (JCUH) | 70s | F | 20 | Ischaemic | III | CRTD | A 200 mg once a day | 0 |
A, amiodarone; CRTD, biventricular implantable defibrillator; F, female; ICD, implantable defibrillator; JCUH, James Cook University Hospital Middlesbrough; LVEF, left ventricular ejection fraction; M, male; Me, mexiletine; NUTH, Newcastle Hospitals NHS Foundation Trust; NYHA, New York Heart Association class; P, propafenone; R, ranolazine; STH, Sheffield Teaching Hospitals; VIVO, view into ventricular onset (non-invasive mapping).